BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
2.070
-0.020 (-0.96%)
At close: Dec 5, 2025, 4:00 PM EST
2.030
-0.040 (-1.93%)
After-hours: Dec 5, 2025, 7:48 PM EST
BioXcel Therapeutics Stock Forecast
BTAI's stock price has decreased by -67.83% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 5 analysts with 12-month price forecasts for BioXcel Therapeutics stock have an average target of 32.8, with a low estimate of 4.00 and a high estimate of 80. The average target predicts an increase of 1,484.54% from the current stock price of 2.07.
Analyst Consensus: Buy
* Price targets were last updated on Sep 15, 2025.
Analyst Ratings
The average analyst rating for BioXcel Therapeutics stock from 5 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 0 | 1 | 1 | 1 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 4 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +383.09% | Sep 15, 2025 |
| Mizuho | Mizuho | Hold Maintains $2 → $4 | Hold | Maintains | $2 → $4 | +93.24% | Sep 12, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +383.09% | Aug 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +383.09% | Aug 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $8 → $10 | Strong Buy | Maintains | $8 → $10 | +383.09% | Aug 15, 2025 |
Financial Forecast
Revenue This Year
625.87K
from 2.27M
Decreased by -72.38%
Revenue Next Year
3.23M
from 625.87K
Increased by 416.40%
EPS This Year
-6.08
from -23.51
EPS Next Year
-3.03
from -6.08
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 735,000 | 6.4M | ||||
| Avg | 625,872 | 3.2M | ||||
| Low | 548,800 | 686,000 |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -67.6% | 920.0% | ||||
| Avg | -72.4% | 416.4% | ||||
| Low | -75.8% | 9.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -4.40 | -2.17 | ||||
| Avg | -6.08 | -3.03 | ||||
| Low | -7.38 | -4.16 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.